Extracellular Vesicles: The Next Generation Theranostic Nanomedicine for Inflammatory Bowel Disease

Li，De Feng1; Yang，Mei Feng2; Xu，Jing3; Xu，Hao Ming3; Zhu，Min Zheng3; Liang，Yu Jie4; Zhang，Yuan5; Tian，Cheng Mei6; Nie，Yu Qiang3; Shi，Rui Yue1; Wang，Li Sheng1; Yao，Jun1

2022

10.2147/IJN.S370784

International Journal of Nanomedicine   Impact Factor & Quartile

1176-9114

1178-2013

The recent rapid development in the field of extracellular vesicles (EVs) based nanotechnology has provided unprecedented opportunities for nanomedicine platforms. As natural nanocarriers, EVs such as exosomes, exosome-like nanoparticles and outer membrane vesicles (OMVs), have unique structure/composition/morphology characteristics, and show excellent physical and chemi-cal/biochemical properties, making them a new generation of theranostic nanomedicine. Here, we reviewed the characteristics of EVs from the perspective of their formation and biological function in inflammatory bowel disease (IBD). Moreover, EVs can crucially participate in the interaction and communication of intestinal epithelial cells (IECs)-immune cells-gut microbiota to regulate immune response, intestinal inflammation and intestinal homeostasis. Interestingly, based on current representative examples in the field of exosomes and exosome-like nanoparticles for IBD treatment, it is shown that plant, milk, and cells-derived exosomes and exosome-like nanoparticles can exert a therapeutic effect through their components, such as proteins, nucleic acid, and lipids. Moreover, several drug loading methods and target modification of exosomes are used to improve their therapeutic capability. We also discussed the application of exosomes and exosome-like nanoparticles in the treatment of IBD. In this review, we aim to better and more clearly clarify the underlying mechanisms of the EVs in the pathogenesis of IBD, and provide directions of exosomes and exosome-like nanoparticles mediated for IBD treatment.

exosome exosome-like nanoparticles extracellular vesicles inflammatory bowel disease theranostic

SCI

English

First ; Corresponding

National Natural Science Foundation of China[81800489];

Science & Technology - Other Topics ; Pharmacology & Pharmacy

Nanoscience & Nanotechnology ; Pharmacology & Pharmacy

WOS:000854413100001

DOVE MEDICAL PRESS LTD

2-s2.0-85137528261

Scopus

1.Department of Gastroenterology,Shenzhen People’s Hospital (The Second Clinical Medical College,Jinan University,The First Affiliated Hospital,Southern University of Science and Technology),Shenzhen,China
2.Department of Hematology,Shenzhen,Yantian District People’s Hospital,China
3.Department of Gastroenterology and Hepatology,Guangzhou Digestive Disease Center,Guangzhou First People’s Hospital (School of Medicine of South China University of Technology),Guangzhou,China
4.Department of Child and Adolescent Psychiatry,Shenzhen Kangning Hospital,Shenzhen,China
5.Department of Medical Administration,Huizhou Institute of Occupational Diseases Control and Prevention,Huizhou,China
6.Department of Emergency,Shenzhen People’s Hospital,(The Second Clinical Medical College,Jinan University,The First Affiliated Hospital,Southern University of Science and Technology),Shenzhen,China

Li，De Feng,Yang，Mei Feng,Xu，Jing,et al. Extracellular Vesicles: The Next Generation Theranostic Nanomedicine for Inflammatory Bowel Disease[J]. International Journal of Nanomedicine,2022,17:3893-3911.

Li，De Feng.,Yang，Mei Feng.,Xu，Jing.,Xu，Hao Ming.,Zhu，Min Zheng.,...&Yao，Jun.(2022).Extracellular Vesicles: The Next Generation Theranostic Nanomedicine for Inflammatory Bowel Disease.International Journal of Nanomedicine,17,3893-3911.

Li，De Feng,et al."Extracellular Vesicles: The Next Generation Theranostic Nanomedicine for Inflammatory Bowel Disease".International Journal of Nanomedicine 17(2022):3893-3911.